…expected to exceed the high-cost risk pool payment threshold. See, DeMartino P, Haag MB, Hersh AR, Caughey AB, Roth JA. A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective. JAMA Pediatr. 2021 Jun 1;175(6):617-623. doi: 10.1001/jamapediatrics…
…expected to exceed the high-cost risk pool payment threshold. See, DeMartino P, Haag MB, Hersh AR, Caughey AB, Roth JA. A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective. JAMA Pediatr. 2021 Jun 1;175(6):617-623. doi: 10.1001/jamapediatrics…
…-CLIN29 2019), Groningen, The Netherlands, January 31, 2019. Edited by: Hessel Haagsma, Tim Kreutz, Masha Medvedeva, Walter Daelemans, Malvina Nissim Submitted by: Malvina Nissim Published on CEUR-WS: 22-Sep-2019 ONLINE: URN: urn:nbn:de:0074-2453-4 ARCHIVE: Vol-2452 Joint IJCAI-2…
…-CLIN29 2019), Groningen, The Netherlands, January 31, 2019. Edited by: Hessel Haagsma, Tim Kreutz, Masha Medvedeva, Walter Daelemans, Malvina Nissim Submitted by: Malvina Nissim Published on CEUR-WS: 22-Sep-2019 ONLINE: URN: urn:nbn:de:0074-2453-4 ARCHIVE: Vol-2452 Joint IJCAI-2…